Permissive Hypercapnia in Heart Failure Patients with Cheyne-Stokes Breathing

Understanding Cheyne-Stokes Breathing in Heart Failure

Cheyne-Stokes respiration is characterized by an oscillatory pattern of respiration with crescendo-decrescendo changes in tidal volume alternating with periods of apnea or hypopnea, occurring primarily during light sleep, and is associated with advanced heart failure, according to the American Academy of Sleep Medicine 1
Cheyne-Stokes breathing occurs primarily during light sleep and is under chemical control, as stated by the American Academy of Sleep Medicine 2
The breathing pattern is associated with respiratory alkalosis, characterized by low carbon dioxide levels and high pH, as noted by the American Academy of Sleep Medicine 3

Cheyne-Stokes breathing appears to be a compensatory mechanism that offsets adverse effects of heart failure, improving breathing efficiency and reducing respiratory muscle fatigue, as suggested by the American Academy of Sleep Medicine 3
The periodic rest and hyperventilation phases increase end-expiratory lung volume, which increases oxygen stores and helps overcome restrictive ventilatory defects, particularly beneficial when patients are in a supine position, according to the American Academy of Sleep Medicine 4

Medications that stimulate ventilation can reduce periods of central apneic rest but increase unrelenting hyperventilation, which may be detrimental, and can cause electrolyte disturbances, laryngeal spasm during sleep, and cardiac arrhythmias, as reported by the American Academy of Sleep Medicine 5, 6
Adaptive servo-ventilation, designed to suppress Cheyne-Stokes breathing, has been associated with increased mortality in heart failure patients with reduced ejection fraction, according to the American Academy of Sleep Medicine 5

The American Academy of Sleep Medicine recommends focusing on optimizing guideline-based heart failure therapy as the primary intervention, and recognizing that Cheyne-Stokes breathing may be a marker of heart failure severity rather than a primary therapeutic target 1, 3
The American Academy of Sleep Medicine suggests that Cheyne-Stokes breathing often improves with effective treatment of the underlying heart failure, and interventions specifically aimed at suppressing the breathing pattern should be avoided if heart failure therapy has been optimized 3, 2, 5

The American Academy of Sleep Medicine views Cheyne-Stokes breathing as a sign of significant heart failure, and its presence should prompt thorough evaluation and optimization of heart failure management, with permissive hypercapnia considered after optimal medical therapy for heart failure has been implemented 3

The American Academy of Sleep Medicine defines Cheyne-Stokes breathing as requiring at least 3 consecutive central apneas/hypopneas separated by crescendo-decrescendo breathing with a cycle length ≥40 seconds in heart failure patients, with cycle lengths typically ranging from 45-90 seconds 7
Heart failure-associated Cheyne-Stokes breathing has a long cycle length (45-75 seconds) with a classic crescendo-decrescendo pattern, distinguishing it from other causes of central sleep apnea 7

Longer cycle lengths in Cheyne-Stokes breathing correlate with more severe left ventricular dysfunction, reflecting both extended circulation time and longer respiratory phases between apneas in advanced heart failure 7

Suppressing Cheyne-Stokes breathing with adaptive servo-ventilation may increase mortality in heart failure patients with reduced ejection fraction, suggesting a potential compensatory role for Cheyne-Stokes breathing 8